Trump to impose 100% tariff on China starting November 1
Investing.com - H.C. Wainwright has reiterated its Buy rating and $15.00 price target on Emergent BioSolutions (NYSE:EBS), currently trading at $8 with a P/E ratio of 3.16, following the company’s announcement of a new government contract modification. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.
Emergent BioSolutions, with a market capitalization of $427 million and strong liquidity indicated by a current ratio of 5.66, received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply TEMBEXA oral suspension, according to a press release issued Monday. InvestingPro data reveals 8 additional key insights about EBS’s financial health and growth prospects.
The modification follows the FDA’s recent approval of manufacturing scale-up for TEMBEXA oral suspension, which provides an important option for patients who may have difficulty swallowing due to age or medical status.
This newly exercised contract modification (CLIN0004B) builds upon previously announced options (CLIN0004A and CLIN0005A) from September 2024, all under Emergent’s existing 10-year contract with the U.S. Department of Health and Human Services.
TEMBEXA was originally approved by the FDA in June 2021 for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates, and is formulated as both 100mg tablets and 10mg/mL oral suspension dosed once-weekly for two weeks.
In other recent news, Emergent BioSolutions reported its Q2 2025 earnings, showing a mixed performance. The company achieved an earnings per share of $0.16, surpassing the expected EPS of -$0.10, although its revenue fell short at $141 million compared to the anticipated $174 million. Additionally, Emergent BioSolutions secured a $56 million contract modification to supply the ACAM2000 vaccine to the U.S. government, with deliveries set to begin this month. This contract increases the company’s projected sales for the vaccine and related products to over $120 million this year. In another development, the company received a $17 million contract modification from the Biomedical Advanced Research and Development Authority to supply TEMBEXA oral suspension for smallpox treatment. H.C. Wainwright reiterated its Buy rating and $15.00 price target for Emergent BioSolutions following the announcement of these contracts. The firm also announced a $30 million contract modification for its FDA-approved anthrax vaccine, CYFENDUS. These recent developments reflect the company’s ongoing efforts to expand its government contracts and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.